| Registro completo |
| Provedor de dados: |
BJID
|
| País: |
Brazil
|
| Título: |
A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation
|
| Autores: |
Atalla,Angelo
Maiolino,Angelo
Guimarães,Maria Angélica
Guimarães,Antonio Carlos
Nucci,Marcio
|
| Data: |
2005-08-01
|
| Ano: |
2005
|
| Palavras-chave: |
Acyclovir
Prophylaxis
Stem cell transplantation
|
| Resumo: |
The reactivation of Herpes Simplex virus (HSV) occurs in 70% to 80% of patients submitted to autologous stem cell transplantation (ASCT); it increases the severity of chemotherapy-induced mucositis. Therefore, the use of acyclovir in ASCT patients is considered standard practice. However, the minimum dose needed to prevent reactivation is a matter of debate. We compared two doses of acyclovir in a non-randomized fashion in 59 patients submitted to ASCT: 32 patients received a dose of 125 mg/m² IV every six hours and the subsequent 27 patients received a dose of 60 mg/m² IV every six hours. Viral excretion was evaluated through weekly viral culture of oral swabs. Grade 4 mucositis was more frequent in Group 1 (p= 0.03). The reactivation rates in Groups 1 and 2 were 9% and 4%, respectively (p= 0.62, 95% confidence interval -7 - 18). Prophylaxis with reduced doses of intravenous acyclovir seems to be as effective as a higher dose in inhibiting HSV reactivation, with a significant reduction in cost. Prospective randomized studies are needed to confirm our conclusions.
|
| Tipo: |
Info:eu-repo/semantics/article
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702005000400010
|
| Editor: |
Brazilian Society of Infectious Diseases
|
| Relação: |
10.1590/S1413-86702005000400010
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Infectious Diseases v.9 n.4 2005
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
